Navigation Links
NKTR-102 Shows High Response Rate and Sustained Duration of Response in Women with Platinum-Resistant/Refractory Ovarian Cancer Previously Treated with Doxil®
Date:6/5/2011

4

4

4Previous Platinum Regimens  1

13%

35%

24%  2

56%

24%

39%  3

25%

18%

21%  4+

6%

24%

15%Prior bevacizumab

6%

24%

15%Prior gemcitabine

56%

59%

58%Prior taxane

100%

100%

100%TABLE 2. Efficacy Results: Objective Response Rates by RECIST and GCIG in Subpopulation Receiving Prior Treatment with PLDNKTR-102NKTR-102145 mg/m2  q14d145 mg/m2q21dRECISTN (evaluable)16

14Confirmed + Unconfirmed

4 (25%)

4 (29%)Confirmed

3 (19%)

3 (21%)Duration of Confirmed Response (months, range)

4.2 (3-14)

4.4 (3-9)GCIGN (evaluable)

16

17Confirmed + Unconfirmed

8 (50%)

6 (35%)Confirmed

6 (38%)

6 (35%)CA-125N (evaluable)

15

14Confirmed

6 (40%)

5 (36%)*Only patients with measurable disease/CA-125 at baseline were considered evaluable.TABLE 3. Safety Results in Subpopulation Receiving Prior Treatment with PLDMost Common Drug-related Grade 3 and 4

Adverse Events > 5% or event of interest

N (%) NKTR-102

145 mg/m2

q14d

N=16

NKTR-102

145 mg/m2

q21d

N=17Grade 3

Grade 4

Grade 3

Grade 4Diarrhea

5 (31%)

0

3 (18%)

0Hypokalemia

5 (31%)

1 (6%)

0

0Nausea

5 (31%)

0

1 (6%)

0Dehydration

3 (19%)

0

1 (6%)

0Fatigue

1 (6%)

0

3 (18%)

0Vomiting

4 (25%)

0

0

0Neutropenia

1 (6%)

0

1 (6%)

1 (6%)Anaemia

2 (12.5%)

0

0

0Decreased appetite

1 (6%)

0

1 (6%)

0Hyponatraemia

2 (13%)

0

0

0Lymphophenia

1 (6%)

0

1 (6%)

0Note: There wa
'/>"/>

SOURCE Nektar Therapeutics
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. NKTR-102 Demonstrates Sustained Clinical Benefit in 46% of Patients with Metastatic Breast Cancer in Data Presented at 2011 American Society of Clinical Oncology Annual Meeting
2. Nektar Announces New Phase 2 Data for NKTR-102 to Be Presented at 2011 ASCO Annual Meeting
3. FDA Grants Orphan Drug Designation for Nektars Investigational Drug, NKTR-102, for Treatment of Women with Ovarian Cancer
4. NKTR-102 Demonstrates Significant Efficacy as Single-Agent in Second- or Third-Line Treatment in Metastatic Breast Cancer Patients
5. NKTR-102 Shows Encouraging Anti-Tumor Activity in Ovarian Cancer in Phase 1 and Preclinical Data Presented at the ECCO 15 and 34th ESMO Multidisciplinary Congress
6. Nektar Announces Expanded Phase 2 Clinical Development Plan For NKTR-102 (PEG-irinotecan)
7. Nektar to Webcast Presentation of Phase 1 Clinical Results for Lead Small Molecule PEG-Oncolytic Program, NKTR-102 (PEG-irinotecan)
8. Significant Anti-Tumor Activity of NKTR-102 in Patients With Refractory Solid Tumors; Interim Data Published in ASCO 2008 Proceedings
9. Additive Anti-Tumor Activity of NKTR-102 in Combination With Bevacizumab Highlighted in Positive Preclinical Data Presented at AACR Meeting
10. Nektar Commences Phase 2 Clinical Development Program for NKTR-102 (PEG-Irinotecan) in Colorectal Cancer
11. NKTR-102 (PEG-Irinotecan) Demonstrates Significant Tumor Growth Inhibition In Multiple Preclinical Tumor Models
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/15/2014)... DUBLIN , Dec. 12, 2014 Research and ... ( http://www.researchandmarkets.com/research/ms3j8c/cardiac ) has announced the ... Estimates and Forecasts, 2012-2018"  report to their offering. ... by 2016. The North America ... while Europe claims approximately 25% ...
(Date:12/15/2014)... Israel , Dec. 15, 2014  Immune Pharmaceuticals Inc. ... that its Board of Directors has elected Mr. Daniel Kazado ... who continues as Chief Executive Officer of Immune. Mr. Kazado ... 2013. Immune,s new Chairman, Mr. Daniel Kazado ... shareholders and to continue to support the strategic vision of ...
(Date:12/15/2014)... and BRIDGEWATER, N.J. , ... REGN) and Sanofi US (EURONEXT: SAN and NYSE: SNY) ... organizations to launch Cholesterol Counts , an awareness ... cholesterol, their numbers, and the risks associated with high ... www. CholesterolCounts .com to take a brief ...
Breaking Medicine Technology:Cardiac Guidewires - Global Trends, Estimates and Forecasts, 2012-2018 2Cardiac Guidewires - Global Trends, Estimates and Forecasts, 2012-2018 3Cardiac Guidewires - Global Trends, Estimates and Forecasts, 2012-2018 4Immune Pharmaceuticals Elects Daniel Kazado as New Chairman of the Board. 2Immune Pharmaceuticals Elects Daniel Kazado as New Chairman of the Board. 3Immune Pharmaceuticals Elects Daniel Kazado as New Chairman of the Board. 4Have You Been Counted? Regeneron and Sanofi US Join Forces with Leading Cardiovascular Organizations to Raise Awareness of Cholesterol 2Have You Been Counted? Regeneron and Sanofi US Join Forces with Leading Cardiovascular Organizations to Raise Awareness of Cholesterol 3Have You Been Counted? Regeneron and Sanofi US Join Forces with Leading Cardiovascular Organizations to Raise Awareness of Cholesterol 4Have You Been Counted? Regeneron and Sanofi US Join Forces with Leading Cardiovascular Organizations to Raise Awareness of Cholesterol 5Have You Been Counted? Regeneron and Sanofi US Join Forces with Leading Cardiovascular Organizations to Raise Awareness of Cholesterol 6
(Date:12/17/2014)... -- Expectant parents should leave prenatal picture-taking to medical ... Use of ultrasound imaging and heartbeat monitors to get ... agency warns. "Although there is a lack ... and heartbeat monitors, prudent use of these devices by ... FDA biomedical engineer, said in an agency news release. ...
(Date:12/17/2014)... HealthDay Reporter , TUESDAY, Dec. 16, ... America, and work commitment is a big reason why, new ... said Dr. Mathias Basner, an assistant professor of sleep and ... of Medicine. A time-use survey of nearly 125,000 Americans, ... main activity exchanged for sleep. Short sleepers -- those who ...
(Date:12/15/2014)... 15, 2014 South Florida’s leading urgent care ... can be a daze of hassle, hustle, and bustle that ... decking halls, to burns when making special meals and heartburn ... can happen at any time. To prevent this season of ... made a list of helpful and healthful holiday tips to ...
(Date:12/15/2014)... News) -- Expert pilots process visual information more efficiently ... better decisions during landings, a new study shows. ... pilots to master, and 36 percent of all airplane ... final approach and landing. Researchers monitored the brain ... pilots while they were at the controls of a ...
(Date:12/15/2014)... 15, 2014 At the leading, long-established ... AutismOne and Focus Autism will welcome ... research on the effects of toxins to children’s health, ... information. , Luminaries such as Dr. Lucija Tomljenovic ... with esteemed, credentialed colleagues of the United States to ...
Breaking Medicine News(10 mins):Health News:FDA Warns Against Fetal 'Keepsake' Videos 2Health News:Work Steals Valuable Sleep Time, Study Finds 2Health News:Work Steals Valuable Sleep Time, Study Finds 3Health News:MD Now Urgent Care Presents Healthy Holiday Tips 2Health News:MD Now Urgent Care Presents Healthy Holiday Tips 3Health News:Study Shows Why Expert Pilots Are Experts 2Health News:AutismOne and Focus Autism Collaborate on Scientific Conference; International Group of Researchers to Present in Chicago, May 2015 2Health News:AutismOne and Focus Autism Collaborate on Scientific Conference; International Group of Researchers to Present in Chicago, May 2015 3
... has decided to enter rehab in order to get rid of ... ,Calum, who was recently snapped in a sleazy romp with two ... ,"Im a bad boy. I go out and ... debauched things with the wrong women. Ive been sowing my oats ...
... But the man who set off the panic is ... in the disease. The man himself has been identified as ... coughing, has no fever and does not appear to be ... staff at the National Jewish Medical and Research Center will ...
... to double current funding levels for the President's Emergency ... five years after the program's original mandate expires next ... authorized $15 billion over five years for HIV/AIDS and ... to the Global Fund To Fight AIDS, Tuberculosis and ...
... Technologies, Inc. (NTI) announced today the presentation of new ... and updates on the clinical development of their ... ischaemic stroke at the 16th annual European Stroke Congress ... a defibrinogenating agent derived from the venom of the ...
... announced today that the U.S. Food and Drug ... (NDA) of its marketing partner, Critical Therapeutics, ... CR(TM) offers twice-daily, extended-release dosing. Under a co-promotion ... 2007, DEY will co-market Critical Therapeutics' ZYFLO CR(TM). ...
... Month, and to commemorate the occasion 27 walks will ... to Cure Scleroderma walks all share a common purpose: ... ,"These events galvanize our patient communities while raising the ... disease," said Frances Waldron, chief executive officer of the ...
Cached Medicine News:Health News:American Who Set Off TB Scare Doing Well in Hospital 2Health News:American Who Set Off TB Scare Doing Well in Hospital 3Health News:Bush Announces Request for $30B, Five-Year Extension of PEPFAR 2Health News:Investigational Drug Being Pursued for the Treatment of Ischaemic Stroke 2Health News:FDA Approves ZYFLO CR(TM) (Zileuton) for Chronic Treatment of Asthma 2
... Special Low-profile Hourglass Jaw Design ... Through A Minimal Incision.,Mirror Polished Blades ... Acting Handle Mechanism Offers Control Over ... Prevent The Lens From Tilting During ...
... Opening Is Designed To Pinch And ... A Separate Cystotome. The 11mm Jaws Are Formed,To ... Incision.,The Distal Jaws Have Platforms, And The Proximal ... Pick Up Of Iris. The Unique Jaw Structures ...
2.5V Halogen source, fiber-optic delivery, 3X magnification, pocket-sized....
... offer patented Sensomatic® handles that ... up and switch off when ... of light from 2.5V halogen ... of examination area. Used ...
Medicine Products: